literature-driven analysis at the intersection of healthcare, economics and policy.
-
Connected Care, Disconnected Access: What Wearables & Digital Health Innovations Reveal About The Next Era Of Medicine
Read more: Connected Care, Disconnected Access: What Wearables & Digital Health Innovations Reveal About The Next Era Of MedicineEarlier this year, Eli Lilly partnered with OURA to help patients on its GLP-1 drugs like Mounjaro track their health more closely on the OURA app. Whilst both companies quickly confirmed no data would be shared between them (unless the user gave permission do to so), this deal sits inside a much bigger health tech…
-
The Gender Health Gap: A Systematic Failure in Diagnosis, Research & Policy
Read more: The Gender Health Gap: A Systematic Failure in Diagnosis, Research & Policy$1 Trillion USD, annually. That’s how much economic growth the world could see by 2040 if the gender gap in healthcare was addressed. With women living over 25% of their lives in poor health, compared to men and making up nearly half of the global population, only 5% of global R&D fundings goes to women’s…
-
Cancer Therapies That Work But NICE Won’t Fund – What They Mean for Patients.
Read more: Cancer Therapies That Work But NICE Won’t Fund – What They Mean for Patients.NICE rejected Enhertu® for HER2-low breast cancer in 2024 – the first breast cancer treatment not recommended by the drug regulatory body in 6 years. This is not because the treatment doesn’t work, but because it costs more per quality-adjusted life year (QALY) than the NHS can afford. Rejected drugs can sometimes become accessible via…
-
GLP-1 Medications: Side effects, Uncertainty and the Socioeconomic Cost of Rapid Adoption
Read more: GLP-1 Medications: Side effects, Uncertainty and the Socioeconomic Cost of Rapid AdoptionOver 50% of GLP-1 users discontinue use due to side effects, with two-thirds regaining the weight loss – yet the socioeconomic impact of this cycle is rarely analysed or considered in policy decisions. Approx. 95% of access is through private pathways beyond NHS structured frameworks; whilst people in least deprived areas are most likely to…
-
Prevention: The health inequality contributor that needs more attention
Read more: Prevention: The health inequality contributor that needs more attentionPrevention is the policy we keep ignoring… Preventative care is allocated only 5.2% of the national healthcare budget (ONS, 2022) despite years of research showing the greater impacts of prevention on healthcare and society. Preventable diseases have a multi-billion pound impact on our national health services, with further detriments on our society and economy through…
